Integra LifeSciences (IART), a global medical bionic implant company, disclosed last week that the U.S. Food and Drug Administration successfully completed an inspection of its regenerative medicine facility in Plainsboro, New Jersey. The FDA issued a warning letter to the company after inspecting its Plainsboro facility in the third quarter of 2011. At the conclusion of the recent inspection, the FDA found that the company had addressed the issues raised in the warning letter and previous inspectional observations, and it issued no further inspectional observations.
Integra's stock underperformed the market and its peers due to the FDA warning. Now in the absence of any warning the stock is poised to scale higher. In this article I will...
Only subscribers can access this article, which is part of the PRO research library covering 3,570 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: